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Background: With 14.234 diagnoses and over 4047 deaths reported in 2007, colorectal cancer (CRC) is the second
most common cancer and second most common cause of cancer-related mortality in Australia. The direct treatment
cost has recently been estimated to be around AU$1.2 billion for the year 2011, which corresponds to a four-fold
increase, compared the cost reported in 2001. Excluding CRCs due to known rare genetic disorders, 20% to 25% of all
CRCs occur in a familial aggregation setting due to genetic variants or shared environmental risk factors that are yet to
be characterised. A targeted screening strategy addressed to this segment of the population is a potentially valuable
tool for reducing the overall burden of CRC.
Methods: We developed a Markov model to assess the cost-effectiveness of three screening strategies offered to people
at increased risk due to a strong family history of CRC. The model simulated the evolution of a cohort of 10,000 individuals
from age 50 to 90 years. We compared screening with biennial iFOBT, five-yearly colonoscopy and ten-yearly colonoscopy
versus the current strategy of the Australian National Bowel Cancer Screening Programme (i.e. base case).
Results: Under the NBCSP scenario, 6,491 persons developed CRC with an average screening lifetime cost of AU$3,441
per person. In comparison, screening with biennial iFOBT, colonoscopy every ten years, and colonoscopy
every five years reduced CRC incidence by 27%, 35% and 60%, and mortality by 15%, 26% and 46% respectively.
All three screening strategies had a cost under AU$50,000 per life year gained, which is regarded as the upper limit of
acceptable cost-effectiveness in the Australian health system. At AU$12,405 per life year gained and an average lifetime
expectancy of 16.084 years, five-yearly colonoscopy screening was the most cost-effective strategy.
Conclusion: The model demonstrates that intensive CRC screening strategies targeting people at increased risk
would be cost-effective in the Australian context. Our findings provide evidence that substantial health benefits
can be generated from risk-based CRC screening at a relatively modest incremental cost.
Keywords: Colorectal cancer, Family history, Screening, Cost-effectivenessBackground
With 14.234 diagnoses and over 4047 deaths reported in
2007, colorectal cancer (CRC) is the second most common
cancer and second most common cause of cancer-related
mortality in Australia [1]. The direct treatment cost has
recently been estimated to be around AU$1.2 billion for the
year 2011, which corresponds to a four-fold increase
compared the cost reported in 2001 [2,3].
Approximately 10-15% of the population have a family
history of CRC, which increases the disease personal risk
by two-four fold (excess familial risk) depending on the* Correspondence: drissao@unimelb.edu.au
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unless otherwise stated.number of relatives affected, the degree of relationship of
the affected relatives and the age of diagnosis [4]. Even
after excluding CRCs due to known genetic disorders such
as Lynch syndrome and familial adenomatous polyposis
(FAP), the cause of about 25-50% of this excess familial
risk is unknown [4,5] but could be due to specific genetic
variants or shared environmental risk factors that are yet
to be characterised [6].
The focus of this study is people at increased risk
of CRC because of a strong family history of CRC.
Here, we define strong family history as people with
one first-degree relative diagnosed before the age of
55 years, or with two first-degree relatives or onel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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of the family diagnosed at any age.
On average, these people have an estimated risk of
developing CRC between three and six times higher
compared to the average risk population [7,8].
A targeted screening strategy addressed to this segment
of the population is a potentially effective approach
to reduce the burden of CRC.
Whilst three randomised controlled trials have demon-
strated that screening with faecal occults blood test
(FOBT)—followed with a diagnostic colonoscopy in case
of positive test—is effective in reducing CRC incidence
and mortality in the average risk population, no direct
evidence exists to support the effectiveness of screening
in people in this increased risk category. Based on expert
opinion, current guidelines generally advise that persons
with a strong family history of CRC should initiate
screening at an earlier age or undergo more intensive
screening compared to the average risk population [9-11].
For example, current guidelines in the United States recom-
mend colonoscopy screening every 10 years starting at age
40 or ten years younger than the age of the first diagnosis
of CRC in the family [11,12] Similarly, the Australian
National Health and Medical Research Council (NHMRC)
guidelines designate persons in this risk category as being
at “moderately increased-risk” of CRC and recommend
colonoscopic screening every five years from the earlier
of age 50 years or ten years younger than the age of the
first diagnosis of CRC in the family [10].
Similar to the clinical effectiveness, the cost-effectiveness
of CRC screening in the average-risk population, based on
various strategies and using different screening modalities,
has been established by several studies [13-18]. Pignone
and colleagues identified six Australian studies published
between 1996 and 2010. All of these studies concluded that
annual and biennial CRC screening by guaiac-based or
immunochemical faecal occult blood test (iFOBT) is
cost-effective, with cost per life-year gained under $55,000
per year in 2010 Australian dollars [19]. Conversely, very
few economic evaluation studies have focused on the
economic aspects of screening in people at increased risk
of CRC due to a strong family history, despite the fact that
up to a quarter of all CRC cases are diagnosed in this
segment of the population. We identified only two recent
studies, conducted in Spain and the United States,
assessing the economic implication of implementing a
family history-based CRC screening programme [20,21].
Both studies found colonoscopic screening every five years
starting at age 40 years to be a cost-effective strategy for
people with a family history of CRC.
There is a strong rationale for designing risk-based
CRC screening policies (i.e. intensiveness of screening
based on risk) as this would, theoretically at least, permit a
more efficient allocation of limited health care resources[22]. However, such policies, based on a personalised
approach of CRC screening, would also have an important
economic impact on the health care system as a whole
(e.g. familial risk assessment programmes, higher number
of screening colonoscopies and more specialists able to
perform them) and overall public health implications
which need to be investigated.
The main objective of this analysis was to provide
an economic evaluation for people at increased risk of CRC,
based on Australian data assessing the cost-effectiveness
of biennial iFOBT, five-yearly colonoscopic screening
starting at age 50 years, and ten-yearly colonoscopic
screening starting at age 50 years to the current program
of the National Bowel Cancer Screening programme of
Australia (NBCSP) which currently consists of a one-off
iFOBT screening offered at age 50, 55, 60 and 65 years (9)
irrespective of family history.
Methods
We developed a Markov microsimulation model to
simulate the natural history of CRC and to evaluate
costs and outcomes of screening. Figure 1 summarises
the model structure and assumptions. Four CRC screening
strategies were superimposed on this model to simulate
the evolution of a hypothetical population of 10,000
individuals at “moderately increased risk” of CRC due
to a strong family history-as defined by the current
NHMRC guidelines [10].
Based on current understanding of the variability in
the natural history of the disease, we created nine
mutually exclusive, possible health states (from normal to
death due to CRC or other causes) and specified transition
probabilities for movements between these health states.
An individual can remain in the same health state or move
to another health state according to the predetermined
transition probabilities. Costs and health outcomes
(including life expectancy) were assigned to each state
and transition. The software TreeAge Pro was used to
implement the model [23].
Model parameters
The parameters used in the Markov model are presented
in Table 1. All individuals in the simulated cohort
entered the model at age 50 years and were able to exit
the model only when they turned 90 years of age or via
one of the two absorbing states. Participants’ initial state
was distributed to normal, adenoma or CRC according
the corresponding prevalences at age 50 years based on
assumptions provided below (Table 2). The model
assumed that around 85% of all CRCs developed from
large adenomas, which developed from small adenomas,
which arose from normal bowel.
Age-specific incidence rates of small polyps, large
polyps, adenomas and CRC at different stages were
Figure 1 Markov process for disease natural history and colorectal cancer diagnosis. Persons in the modelled cohort go through this cycle
every year from age 50 to 90.
Ouakrim et al. BMC Cancer 2014, 14:261 Page 3 of 10
http://www.biomedcentral.com/1471-2407/14/261obtained from the health economics review conducted
in 2008 by Bishop et al. for the Cancer Institute of
New South Wales [24].
To reflect a cohort of persons in the “moderately
increased risk” category (defined as: one 1st degree relative
with CRC diagnosed before age 55 years; or two 1st or
one 1st and one 2nd degree relative/s on the same
side of the family diagnosed at any age), we followed
the approach adopted by Ladabaum et al. [20] and
Ramsey et al. [21]. We multiplied the population’s
prevalence of adenoma and CRC at age 50 by a factor
of four (relative risk (RR) = 4) on the basis of the
current NHMRC criteria of 3 to 6 fold increased risk in
this population compared to the average risk population
[10]. We similarly, multiplied the estimates of incidence of
small polyps, large polyps and CRC at different stages for
the general population by four to calculate the age-specific
transition probabilities and determine the participants’
progression through the different cycles of the model. In
the sensitivity analysis, we varied the RR between 3 and 6.
Age-specific probabilities of death due to causes other
than CRC were obtained from life tables published by
the Australian Institute of Health and Welfare [25].
Stage-specific annual CRC mortality rates were based onrecent five-year survival data derived from the BioGrid
Australia dataset and presented by Tran and colleagues [3].
Screening programmes
We compared four alternative CRC screening strategies:
1. Screening according to the current NBCSP
programme. Under this screening scenario, which
was used as the baseline strategy in the model,
participants were invited to undertake CRC
screening with an immunochemical iFOBT at age
50, 55, 60 and 65 years (Usual Care).
2. iFOBT biennial screening (every two years) from age
50 years (iFOBT2).
3. Colonoscopy screening every five years starting at
age 50 years. This strategy reflects the current
screening recommendation for people at moderately
increased risk of CRC (COLO5).
4. Colonoscopy screening every ten years starting at
age 50 years (COLO10).
In both iFOBT strategies (Usual Care and iFOBT2), a
person invited to screen could “choose” to undertake
(screeners) or to decline screening (non-screeners). We
Table 1 Parameters of the model
Variable Value Reference
Natural history
Age-specific incidence Adenoma <10 mm
50-54 0.24 Bishop et al. (derived from
prevalence and incidence data







































Dukes’ C 0.085 Tran et al.
Dukes’ D 0.282
Table 1 Parameters of the model (Continued)
Probability of CRC diagnosis without
screening programme






Sensitivity for CRC 0.479 Bishop et al. (table 36)
Sensitivity for polyps’ 0.2119 Bishop et al. (table 36)
Specificity 0.9146 Bishop et al. (table 36)





Sensitivity for CRC 0.95 Bishop et al. (table 36)
Sensitivity for polyps 0.85 NHMRC 2005
Specificity 1 Bishop et al. (table 36)
Participation 40% Assumption
Cost per activity per individual (AU$)
iFOBT (invitation + test kit) $10.00 Bishop et al. (table 40)
iFOBT pathology $20.00





Annual CRC treatment costs per
individual (AU$)
CRC Dukes’ A $1,716.00 Tran et al.
CRC Dukes’ B $4,114.00
CRC Dukes’ C $9,990.50
CRC Dukes’ D $35,578.00
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on the participation rate observed in the NBCSP reported
in the latest monitoring report of the programme [26].
The proportion of screeners with positive (faecal occult
blood detected) or negative tests (no faecal occult blood
detected by FOBT) was determined by the participant’s
probability of disease status (i.e. presence of adenoma or
CRC) and the diagnostic accuracy of the test (i.e. sensitivity
and specificity). Participants with negative tests were
re-invited to screen according to the protocol of each
iFOBT-based screening strategy. We assumed that all
screeners with a positive iFOBT result were eligible for a
follow-up diagnostic colonoscopy referred by a general
practitioner. The compliance for the recommended diag-
nostic procedure was also based on the compliance
Table 2 Possible states for cohort to enter the model
State Description Probability*
Normal No abnormality 0.78
Adenoma <10 mm Individual has adenoma that is <10 mm in diameter 0.1668
Adenoma ≥10 mm Individual has adenoma that is ≥10 mm in diameter 0.0464
Surveillance Individuals are in the surveillance state once they have had an adenoma ≥ 10 mm removed 0
CRC Dukes’ A Individual has developed CRC and is at Dukes stage A 0.0036
Treatment Dukes’ A Individual with Dukes stage A has been diagnosed and will not take part in any further screening 0
CRC Dukes’ B Individual has developed CRC and is at Dukes stage B 0.0016
Treatment Dukes’ B Individual with Dukes stage B has been diagnosed and will not take part in any further screening 0
CRC Dukes’ C Individual has developed CRC and is at Dukes stage C 0.0012
Treatment Dukes’ C Individual with Dukes stage C has been diagnosed and will not take part in any further screening 0
CRC Dukes’ D Individual has developed CRC and is at Dukes stage D 0.0004
Treatment Dukes’ D Individual with Dukes stage D has been diagnosed and will not take part in any further screening 0
Dead CRC Death from CRC 0
Dead other causes Death from colonoscopy 0
*Based on Bishop et al.’s prevalence estimates (table 32) [24]. The original figures were multiplied by a factor of 4 for this analysis (methods section).
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firmed the presence of a small adenoma (<10 mm), a poly-
pectomy was assumed to having been performed and the
participant returned to the normal state in the natural his-
tory model. Subjects with large adenomas (≥10 mm) exited
the screening programme after treatment and were
followed up with five-yearly surveillance colonoscopy as
recommended in the current NHMRC guidelines [10].
For colonoscopy-based screening strategies, a similar
logic to that of iFOBT-based screening was applied, the
only differences being the direct removal of any detected
polyp and the use of colonoscopy values for sensitivity
and specificity. In the base case model, level of screening
uptake was determined based on a meta-analysis of eight
studies reporting colonoscopy screening participation
rates for people at increased risk of CRC due to family
history [27]. Subjects with a CRC diagnosed through
screening entered a treatment state, according to their
CRC stage, and progressed through increasing disease
stages until the end of the Markov process. They were
able to exit the model only via death due to CRC or
other causes. Subjects who decline CRC screening, those
with false negative results (existing faecal blood, polyp
or CRC tumour undetected) and those who decline diag-
nostic colonoscopy after a positive iFOBT returned to
the disease natural history.
Costs
For this analysis we adopted a third-party payer (health
care system) perspective. Only direct costs, such as unit
cost or annual costs related to screening and diagnostic
tests, adenoma surveillance and CRC treatment were
taken into account. Indirect costs related to production
loss due to undergoing screening, colonoscopy orhospitalisation, were not considered in this analysis.
Screening and diagnostic costs were based on the estimates
reported by Bishop et al. [24]. For iFOBT based screening,
costs included those needed for the organisation of
the screening campaign (public information, programme
development, infrastructure and coordination) and pur-
chasing, distributing and interpreting the tests (pathology
processing and information costs) as well as the diagnostic
follow up of positive iFOBTs. For colonoscopy based
screening strategies, we assumed the same programme
organisation and colonoscopy test costs as for the FOBT
screening strategies.
Annual costs of treating CRC according to stage at
diagnosis were derived from lifetime treatment costs:
AU$34,337 for treating a Dukes’ A CRC, AU$53,487 for
Dukes’ B, AU$79,924 for Dukes’ C and AU$71,156 for
Dukes’ D, and represent the average cost to the Australian
health system for an individual diagnosed with CRC over
the course of their life [3]. To calculate predicted costs
and outcomes in terms of their present value, all future
costs and outcomes were discounted at an annual rate of
five percent (the standard discount rate currently used by
Australian health technology assessment agencies such as
the Pharmaceutical Benefits Scheme). This reflects the
advantage an individual gets from receiving a benefit
earlier or incurring a cost later in time and is known as
time preference [28]. Here, the discount rate adjusts for
policy maker’s time preference for present over future
outcomes in terms of the costs and effects resulting from
each screening strategy. The performance of each screen-
ing strategy was measured using the incremental cost-
effectiveness ratio (ICER). This indicator is defined as the
cost for each unit increase in effect and is obtained by
calculating the difference in cost between two alternative
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between the same strategies [29]. We also determined the
total number of CRC cases by stage, and average life years
gained (LYG) and costs per person. Sensitivity analyses
were conducted to assess the impact of different screening
participation rates and CRC incidence risk on the model’s
results. To relate colonoscopy utilisation to the number of
lives saved, the total number of procedures performed was
divided by the total CRC deaths avoided in each screening
scenario compared with the NBCSP.
Results
Table 3 presents the results of the base-case model. Under
the Usual Care screening scenario (one-off iFOBT
screening offered at age 50, 55, 60 and 65), 6,491 out of a
cohort of 10,000 “moderately increased-risk” 50 year-old
people would develop CRC over 40 years (to age 90) with
an average lifetime cost of AU$3,441 per person.
Compared to the NBCSP, the iFOBT2, COLO10 and
COLO5 screening strategies reduced the number of CRC
cases by 27%, 35% and 60% and CRC mortality by 15%,
26% and 46% respectively. All three approaches resulted
in more LYG and were more costly than Usual Care.
Five-yearly colonoscopy screening starting at age 50 was
the most costly option with a lifetime cost estimated to be
AU$8,734 per person but also provided the highest LYG
of all the screening strategies.
The incremental cost-effectiveness ratios of the different
screening strategies compared to Usual Care are shown in
Table 4. These ratios were AU$8,306 and AU$12,405 per
LYG for COLO10 and COLO5 respectively. iFOBT2 was
dominated by both screening approaches in the model
(Figure 2). The COLO10 strategy had the lowest ICER
compared to usual care. However, with a superior clinical
effect (longer life expectancy and 60% reduction ofTable 3 Number of expected clinical events for each screenin
NBCSP screening
CRC cases occurring per 10,000 persons from age
50 to 90 years
6,491






Deaths attributable to CRC 983
Reduction in CRC mortality compared with NBCSP
Total Number of colonoscopies 21,333
Number of colonoscopies per life saved
iFOBT2: immunochemical faecal occult blood test, COLO5: colonoscopy screening evincident CRC cases over the 40-year period) and the
lowest number of colonoscopy procedures needed to
save one life, COLO5 screening appeared as the most
cost-effective strategy of the models compared.
Sensitivity analyses showed that above 20% participation
rate the level of colonoscopy screening uptake was not a
very influential parameter on the ICER (Table 5). For
example, in a direct comparison with the NBCSP scenario,
with a 20% screening participation rate, the ICERs for the
COLO5 and COLO10 strategies were $9,108 and $7,835
per LYG respectively. The cost of both strategies were
positively correlated with the level of screening uptake
but increased by only 13% and 24% respectively when
screening participation was set to 90%.
Effects of varying the level of CRC risk (i.e. 3 and 6 fold
risk increase compared to 4 fold increase used in the
base-case model) associated with a strong family history
on the different outcomes of the model are presented in
Additional file 1: Table S1-S4.
Discussion and conclusions
Our aim was to provide an insight into the cost-
effectiveness of CRC screening for people at increased
risk of the disease due to having a strong family history.
We compared three different screening alternatives
to the current NBCSP using Australian data on CRC
incidence, adenoma distribution and cancer stage for
invasive carcinoma. We chose the current NBCSP screen-
ing strategy as the base case scenario in our model instead
of a no screening scenario as we consider this approach
to be more realistic and more relevant to the Australian
context where a population-based screening programme
has been in place since 2006 and will be expended to

















ery five years, COLO10: colonoscopy screening every ten years.
Table 4 Incremental cost-effectiveness ratios for alternative CRC screening strategies compared current NBCSP







NBCSP screening (base case) 3,441 15.545
Colonoscopy every 10 years 6,278 2,837 15.886 8,306
Colonoscopy every 5 years 8,734 2,456 16.084 12,405
ICER: incremental cost-effectiveness ratio.
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LYG, which is regarded as the upper limit of acceptable
cost-effectiveness in the Australian health system [24,31].
An incremental cost of AU$12,405 per LYG, meant
colonoscopy screening every five-year appears to be
the most cost effective strategy of the three tested. In
comparison, the Australian study conducted by Tran and
colleagues (from which we obtained the CRC survival
rates and treatment costs for our modelling) found the
NBCSP, as implemented in 2008, to be cost-effective for
the general population at AU$38,216 per LYG [3].
Ladabaum et al. conducted a cost-effectiveness analysis
including only direct medical costs and using data from
a screening pilot programme implemented in Aragón
(Spain) targeting first-degree relatives of patients with
CRC. The authors analysed the cost-effectiveness of CRC
screening starting at age 40 years comparing colonoscopy
every ten years and colonoscopy every five years, to
no screening. Both screening strategies dominated the
“no screening” option. Similar to our findings, five-yearlyFigure 2 Cost-effectiveness of the screening strategies included in thcolonoscopic screening was found to be the most
cost-effective strategy [20].
In a study conducted in the United States, Ramsey and
colleagues used a validated microsimulation model [32]
adopting a societal perspective (i.e. analysis including
direct and indirect costs of screening) to evaluate the
clinical and economic implications of implementing a
CRC screening programme based on family history in
the United States. Similar to our approach, the authors
used a very specific definition of family history, based on
current CRC screening guidelines. In the model, persons
with a positive family history (i.e. having one FDR diagnosed
with CRC before age 60 or two FDRs diagnosed at any age)
had three alternative colonoscopy-based screening scenar-
ios, which varied by frequencies (five or ten years) and age
at which the screening began (age 40 to age 50). Results
from each one of these screening strategies were then
compared to a “usual care” scenario where colonoscopic
screening was offered every ten years to the entire popula-
tion (average- and increased-risk persons) from agee model.
Table 5 One-way sensitivity analysis of ICER based on screening participation rate
Colonoscopy screening participation rate ICER COLO5 vs. usual care ICER COLO10 vs. usual care
Life years gained per
1,000 persons
ICER (AU$) Life years gained per 1,000 persons ICER (AU$)
10% 81 17,779 - Dominated
20% 346 9,108 148 7,835
30% 492 9,089 272 7,612
40% (reference) 561 9,842 361 8,619
50% 699 9,283 416 9,192
60% 717 10,095 476 9,863
70% 775 10,245 547 9,887
80% 824 10,279 609 9,949
90% 871 10,423 641 10,333
100% 880 11,139 722 10,384
ICER: incremental cost-effectiveness ratio, iFOBT2: immunochemical faecal occult blood test, COLO5: colonoscopy screening every five years, COLO10: colonoscopy
screening every ten years.
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acceptable ICERs (including the usual care option when
compared to no screening) with five-yearly colonoscopy
screening from age 40 years being the most cost-effective
option (US$18,678 per LYG). The study concluded that a
combination of a more aggressive CRC screening strategy
targeting people with a family history, with a programme
addressed to the general population may be a valuable
approach to prevent CRC in the population [21].
In this study we attempted to conduct a similar
analysis in the Australian context where an iFOBT-
based screening programme has been in place since
2006. To our knowledge, this is the first analysis attempt-
ing to measure the economic aspect of different CRC
screening strategies (including NHMRC recommenda-
tions) that target persons at “moderately increased
risk” of CRC in the Australian context. It should be
noted that this category does not include all individ-
uals with a family history of CRC. Our model is particu-
larly relevant to a segment of the population at a
substantially increased risk of CRC—namely, individual
whom CRC family history characteristics place them in
the risk category 2 of the current Australian guidelines
[10]. Persons in this category are more vulnerable to CRC
due to their familial risk but also due to the fact that the
current NBCSP strategy, by definition, does not address
their specific needs in terms of screening modality and
intensity. We believe that there is an urgent need to ad-
just the existing screening programme in order to address
the specific screening requirements for this population.
Our estimates of the number of colonoscopies needed for
each screening scenario represents a proxy for resource
utilization as well as adverse events from screening. Cur-
rently, over 500,000 colonoscopies are performed each
year in Australia [33], a substantial proportion of these
procedures occur outside of the national screeningprogramme [19] and are undertaken by individuals at
average risk of CRC for whom colonoscopy is not recom-
mended as a screening procedure [34]. In this context,
adjusting the current NBCSP to appropriately address the
screening needs of people above average risk of CRC is
likely to mainly consist of a more efficient use of already
existing resources.
The modelling presented here has several limitations.
For example the model assumed that family history of
CRC was known for all participants and did not include
administrative costs associated with the implementation
of a family history assessment.
While the model accounted for the higher incidence
of polyps observed in people with family history of CRC
as a cause of a higher CRC incidence [35], it did not
include information on polyp sojourn time (i.e. preclinical
phase), which determines the rate of cancerous transform-
ation. Polyp behaviour is those with family history is
still not well characterised, particularly the malignancy
transformation rate.
Our analysis was conducted from a third-party payer
perspective and was limited to direct costs only. Indirect
costs such as production loss due to CRC treatment need
be taken into account for a more exhaustive economic
assessment of a family history-based CRC screening
programme. We did not take into account the costs
involved with potential complications from screening
tests, and the combination of screening and administrative
costs. Also, our costs parameters rely heavily on estimates
reported in Bishop et al. review, which was published in
2008. It is possible that some of those estimates might be
out-of-date given the constant progress and changes in
CRC treatment protocols.
In conclusion, our results are consistent with findings
from previous research and present informative prelim-
inary estimates in the perspective of familial risk-based
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screening programme addressed to the average risk popu-
lation. Given limited colonoscopy capacity and budget,
there is an increasing number of investigators calling for a
better inclusion of personal disease risk in the design of
CRC screening policies. The rational of this approach
being that more screening resources should be allocated
to those who would benefit most from more screening
while at the same time reducing the intensity of screening
among those who have less to gain. Several risk prediction
tools have been developed [36,37] and future advances in
genetic testing for CRC variants will facilitate this process,
to allow tailored screening strategies. Our findings suggest
that health benefits can be generated by implementing
more intensive screening to those at increased risk at a
relatively modest incremental cost.
Additional file
Additional file 1: Table S1-S4. Description of data: Results of
cost-effectiveness analysis with three and six fold increased risk of
colorectal cancer.
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